Sentences with phrase «with targeted therapies»

In the case of breast cancer driven by overexpression of the HER2 gene, up to 50 percent of patients treated with targeted therapies eventually develop brain metastases, which are inevitably fatal.

Results for the first of the drug's Phase III clinical trials showed that in combination with targeted therapy, median time to relapse for patients receiving the vaccine was 44.2 months, whereas those who received the placebo went an average of 30.6 months before relapse.

Happily, according to the researchers» report in the Journal of Allergy and Clinical Immunology, they were able not only to describe the new mutation, but also to successfully treat the patient with targeted therapy.

In the latest example, researchers from Penn Medicine and other institutions found that treating metastatic thyroid cancer patients harboring a BRAF mutation with the targeted therapy vemurafenib — originally approved for melanoma patients with the mutation — showed promising anti-tumor activity in a third of patients.

Importantly, while using rosiglitazone in conjunction with targeted therapy reduced tumor growth in both young and aged pre-clinical models, using rosiglitazone alone accelerated tumor growth in young models, while inhibiting it in aged ones.

Treatment for advanced melanoma has seen success with targeted therapies — drugs that interfere with division and growth of cancer cells by targeting key molecules — especially when multiple drugs are used in combination.

Although other cancer - associated proteins have been successfully attacked with targeted therapies in recent years, the myc protein has continued to elude efforts to develop drugs that target it.

«Because transcription factors have proven so difficult to block with targeted therapies, we wanted to see if an alternative approach that targets these defective transcriptional mechanisms would be effective.»

[26] Due to the lack of complete responses with targeted therapy, there has been resurgent interest in immunotherapy.

The recommendation is due in large part to a growing body of evidence demonstrating the clinical benefit of treating patients whose tumors harbor this alteration with targeted therapy.

If we turn off one oncogene with a targeted therapy, another one turns on to rewire some other metabolic pathway.

«We are not there yet, but I can see that we will look to combination treatment with targeted therapies.»

Thousands of patients with an advanced form of lung cancer that carries a specific dysfunctional gene are likely to fare better if treated with a targeted therapy than with traditional chemotherapy, report Dana - Farber Cancer Institute researchers and a team of international collaborators.

There is substantial clinical impact of performing genetic profiling of tumour samples in order to identify specific mutations and match those mutations with targeted therapies; one of the earliest forms of «personalised» or «precision» medicine.

These results suggest a strong correlation between PD - L1 expression and EGFR mutation and between PD - 1 expression and KRAS mutations, supporting further investigation of anti-PD-L1 or anti-PD-1 agents in combination with targeted therapies.

This is significant because while melanoma patients with the mutant BRAF gene can be treated with a targeted therapy, the majority whose tumors encode a normal BRAF have few effective treatment options.

They analyzed the association between body mass index (weight divided by height) and progression - free survival (PFS) and overall survival (OS) in six independent cohorts of patients treated with targeted therapy, immunotherapy or chemotherapy in pivotal trials that led to FDA approval of these drugs.

Among patients whose tumours carried EGFR mutations, and who were treated with targeted therapies, those whose tumours were also PD - L1 positive took longer to progress, and tended toward longer overall survival than PD - L1 negative patients.

«The results of our study could offer new treatment to this population of patients, identifying a subset of malignant pleural mesothelioma who expressed PD - L1 and could be treated with targeted therapies to PD - L1,» Cedres says.

The results suggest this population of patients could be treated with targeted therapies to PD - L1, researchers say.

Most researchers expect that combining such agents (and other anti-metabolism drugs) with targeted therapies or chemotherapy will work better than any single drug can do on its own.

The study involved about 1,900 people whose advanced melanoma was treated with targeted therapy, immunotherapy or chemotherapy.